| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 7 | 2024 | 135 | 3.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 20 | 2024 | 1192 | 2.890 |
Why?
|
| Immunotherapy, Adoptive | 14 | 2024 | 789 | 2.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2024 | 162 | 1.550 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2024 | 184 | 1.550 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2024 | 519 | 1.490 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2023 | 28 | 1.460 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 48 | 1.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2024 | 136 | 1.240 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 177 | 1.170 |
Why?
|
| Graft vs Host Disease | 10 | 2024 | 542 | 1.100 |
Why?
|
| Hematologic Neoplasms | 5 | 2024 | 272 | 1.000 |
Why?
|
| Lymphoma, Follicular | 3 | 2020 | 29 | 0.950 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1229 | 0.830 |
Why?
|
| Hodgkin Disease | 3 | 2020 | 293 | 0.820 |
Why?
|
| Primary Myelofibrosis | 2 | 2020 | 50 | 0.770 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.720 |
Why?
|
| Antigens, CD20 | 1 | 2020 | 37 | 0.720 |
Why?
|
| Aged | 31 | 2024 | 18982 | 0.680 |
Why?
|
| Transplantation Conditioning | 8 | 2020 | 323 | 0.670 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 101 | 0.630 |
Why?
|
| Middle Aged | 33 | 2024 | 25849 | 0.630 |
Why?
|
| Transplantation, Autologous | 6 | 2021 | 295 | 0.620 |
Why?
|
| SEER Program | 1 | 2019 | 193 | 0.620 |
Why?
|
| Rituximab | 5 | 2024 | 156 | 0.610 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 39 | 0.600 |
Why?
|
| Transplantation, Homologous | 5 | 2019 | 657 | 0.590 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 39 | 0.580 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 137 | 0.570 |
Why?
|
| Standard of Care | 1 | 2018 | 128 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1114 | 0.560 |
Why?
|
| Lymphoma | 4 | 2023 | 321 | 0.530 |
Why?
|
| Sulfonamides | 4 | 2024 | 258 | 0.530 |
Why?
|
| Humans | 58 | 2025 | 122633 | 0.520 |
Why?
|
| Doxorubicin | 3 | 2024 | 300 | 0.470 |
Why?
|
| Medicare | 1 | 2018 | 423 | 0.470 |
Why?
|
| Adult | 28 | 2024 | 28881 | 0.470 |
Why?
|
| Recurrence | 5 | 2023 | 1418 | 0.450 |
Why?
|
| Retrospective Studies | 23 | 2024 | 15916 | 0.420 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 6341 | 0.420 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 532 | 0.420 |
Why?
|
| Cyclophosphamide | 6 | 2024 | 420 | 0.410 |
Why?
|
| Pyrazoles | 5 | 2024 | 301 | 0.400 |
Why?
|
| Male | 32 | 2024 | 59714 | 0.380 |
Why?
|
| Survival Analysis | 6 | 2021 | 1466 | 0.380 |
Why?
|
| Treatment Outcome | 16 | 2024 | 12055 | 0.360 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1215 | 0.360 |
Why?
|
| Female | 32 | 2024 | 65117 | 0.360 |
Why?
|
| Allografts | 2 | 2023 | 189 | 0.350 |
Why?
|
| Neoplasms | 2 | 2024 | 2746 | 0.350 |
Why?
|
| Etoposide | 3 | 2024 | 117 | 0.350 |
Why?
|
| Prednisone | 3 | 2024 | 273 | 0.340 |
Why?
|
| Vincristine | 3 | 2024 | 195 | 0.340 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 1676 | 0.330 |
Why?
|
| Pyrimidines | 6 | 2024 | 374 | 0.330 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 1675 | 0.320 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2019 | 10 | 0.320 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 101 | 0.310 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 478 | 0.300 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 267 | 0.300 |
Why?
|
| Survival Rate | 4 | 2019 | 1992 | 0.280 |
Why?
|
| Boron Compounds | 2 | 2024 | 33 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 712 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 252 | 0.270 |
Why?
|
| Young Adult | 8 | 2021 | 8817 | 0.260 |
Why?
|
| Glycine | 2 | 2024 | 160 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 151 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 2 | 2019 | 335 | 0.240 |
Why?
|
| Genetics, Population | 1 | 2025 | 185 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 34 | 0.220 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 645 | 0.220 |
Why?
|
| Haplotypes | 1 | 2025 | 515 | 0.210 |
Why?
|
| Adenine | 2 | 2020 | 99 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 111 | 0.210 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2019 | 11 | 0.200 |
Why?
|
| Autografts | 2 | 2019 | 26 | 0.200 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 858 | 0.200 |
Why?
|
| Piperidines | 2 | 2020 | 196 | 0.200 |
Why?
|
| Prognosis | 3 | 2019 | 4488 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 317 | 0.190 |
Why?
|
| Budesonide | 1 | 2021 | 19 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 193 | 0.190 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.180 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 13 | 0.180 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 105 | 0.180 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 114 | 0.180 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 77 | 0.180 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 67 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 99 | 0.170 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 98 | 0.170 |
Why?
|
| Febrile Neutropenia | 1 | 2019 | 13 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 169 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 203 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 279 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 64 | 0.150 |
Why?
|
| Melphalan | 1 | 2018 | 49 | 0.150 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 16 | 0.150 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 38 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 62 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 104 | 0.150 |
Why?
|
| Etanercept | 1 | 2017 | 39 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 359 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1015 | 0.140 |
Why?
|
| Disease Management | 2 | 2018 | 514 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2022 | 654 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2019 | 193 | 0.140 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 50 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2017 | 338 | 0.140 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 61 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 397 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2018 | 1162 | 0.130 |
Why?
|
| Remission Induction | 3 | 2023 | 300 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2019 | 364 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5019 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 607 | 0.120 |
Why?
|
| United States | 5 | 2024 | 10559 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 2788 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1148 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1240 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 715 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 325 | 0.110 |
Why?
|
| Plasmacytoma | 1 | 2013 | 7 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 710 | 0.110 |
Why?
|
| Cytokines | 1 | 2018 | 1280 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 223 | 0.090 |
Why?
|
| Insurance, Health | 2 | 2024 | 136 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 2 | 2024 | 28 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2013 | 163 | 0.090 |
Why?
|
| Adolescent | 4 | 2023 | 18987 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 284 | 0.090 |
Why?
|
| Outpatients | 2 | 2024 | 254 | 0.090 |
Why?
|
| Nitriles | 2 | 2020 | 144 | 0.080 |
Why?
|
| Methotrexate | 2 | 2024 | 342 | 0.080 |
Why?
|
| Busulfan | 2 | 2020 | 44 | 0.080 |
Why?
|
| Vidarabine | 2 | 2020 | 79 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2020 | 99 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2395 | 0.080 |
Why?
|
| Obesity | 1 | 2018 | 2091 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 501 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2996 | 0.070 |
Why?
|
| Incidence | 3 | 2019 | 3040 | 0.070 |
Why?
|
| Latin America | 1 | 2025 | 89 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2025 | 306 | 0.060 |
Why?
|
| Unrelated Donors | 1 | 2024 | 82 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2023 | 168 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 121 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 121 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 67 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 155 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 253 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2023 | 287 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 678 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2025 | 743 | 0.050 |
Why?
|
| Neutropenia | 1 | 2023 | 202 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 540 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 606 | 0.050 |
Why?
|
| DNA Topoisomerase IV | 1 | 2020 | 10 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 312 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2020 | 21 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 379 | 0.040 |
Why?
|
| Software | 1 | 2025 | 673 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 458 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 6188 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 285 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 369 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2020 | 256 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 49 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 567 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 68 | 0.040 |
Why?
|
| Propylene Glycol | 1 | 2018 | 8 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 864 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 172 | 0.040 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 2 | 0.040 |
Why?
|
| Genome, Human | 1 | 2025 | 1259 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 1292 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 794 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 296 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 371 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2018 | 527 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 9943 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1164 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 524 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1111 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1683 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 490 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 390 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2024 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1003 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1921 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1297 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3283 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2013 | 54 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 4686 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 17430 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 33618 | 0.010 |
Why?
|